Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

MiNK Therapeutics, Inc.

NASDAQ: INKT · Life Sciences · 3 alerts · CIK 1840229

Share price
$9.35Close, Nov 16
Market cap
$48M
Shares outstanding
5.13MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All MiNK Therapeutics, Inc. filings on SEC EDGAR ↗

9:50 AM ET 8-K
Financial Results

MiNK Therapeutics Financial Results

MiNK Therapeutics reported third quarter 2026 financial results, highlighting its first pre-commercial product revenue from agenT-797 via an international named-patient access program. The company also noted its selection for an ARPA-H program with up to $87 million in team-wide funding and the advancement of its randomized Phase 2 ARDS trial.

Term
Q3 2026

“We now have a randomized trial running in critical illness, multiple clinical programs enrolling and a path toward pivotal development. This quarter, physicians outside our trials began requesting agenT-797 for their patients, bringing our first pre-commercial revenue. The same unmodified iNKT cells, from the same donor, that drove a 77% disease control rate in PD-1-refractory gastroesophageal cancer are now in a placebo-controlled trial in ARDS, where nearly four in ten patients die and no effective approved drug changes that outcome. Our focus now is delivering the randomized readout designed to show what these cells can do for these patients.”

Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.